Combination of canagliflozin and puerarin alleviates the lipotoxicity to diabetic kidney in mice

被引:6
|
作者
Zhu, Qian [1 ]
Zhou, Qu [1 ]
Luo, Xiao-li [1 ]
Zhang, Xu-jie [2 ]
Li, San-yu [1 ]
机构
[1] Univ Tradit Chinese Med, Dept Pharm, Hosp Chengdu, Chengdu 610072, Peoples R China
[2] Parexel China Co Ltd, Chengdu 610000, Peoples R China
来源
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY | 2023年 / 27卷 / 03期
关键词
Canagliflozin; Diabetes mellitus; Diabetic nephropathies; Lipotoxicity; Puerarin;
D O I
10.4196/kjpp.2023.27.3.221
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Diabetic kidney disease is one of the most serious complications of diabetes. Although diabetic kidney disease can be effectively controlled through strict blood glucose management and corresponding symptomatic treatment, these therapies cannot reduce its incidence in diabetic patients. The sodium-glucose co -transporter 2 (SGLT2) inhibitors and the traditional Chinese herb "Gegen" have been widely used in diabetes-related therapy. However, it remains unclear whether the combined use of these two kinds of medicines contributes to an increased curative effect on diabetic kidney disease. In this study, we examined this issue by evaluat-ing the efficacy of the combination of puerarin, an active ingredient of Gegen, and canagliflozin, an SGLT2 inhibitor for a 12-week intervention using a mouse model of diabetes. The results indicated that the combination of puerarin and canagliflozin was superior to canagliflozin alone in improving the metabolic and renal function parameters of diabetic mice. Our findings suggested that the renoprotective effect of combined puerarin and canagliflozin in diabetic mice was achieved by reducing re-nal lipid accumulation. This study provides a new strategy for the clinical prevention and treatment of diabetic kidney disease. The puerarin and SGLT2 inhibitor combina-tion therapy at the initial stage of diabetes may effectively delay the occurrence of diabetic kidney injury, and significantly alleviate the burden of renal lipotoxicity.
引用
收藏
页码:221 / 230
页数:10
相关论文
共 50 条
  • [1] Canagliflozin in diabetic kidney disease
    Pavlicek, Vojtech
    DIABETOLOGIE, 2023, 19 (08): : 936 - 937
  • [2] Podocyte lipotoxicity in diabetic kidney disease
    Nishi, Hiroshi
    Nangaku, Masaomi
    KIDNEY INTERNATIONAL, 2019, 96 (04) : 809 - 812
  • [3] The Contribution of Lipotoxicity to Diabetic Kidney Disease
    Schelling, Jeffrey R.
    CELLS, 2022, 11 (20)
  • [4] Ergosterol Alleviates Kidney Injury in Streptozotocin-Induced Diabetic Mice
    Li Ang
    Liu Yuguang
    Wang Liying
    Zhang Shuying
    Xu Liting
    Wang Shumin
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2015, 2015
  • [5] Mst1 knockdown alleviates cardiac lipotoxicity and inhibits the development of diabetic cardiomyopathy in db/db mice
    Xiong, Zhenyu
    Li, Yueyang
    Zhao, Zhengqing
    Zhang, Yan
    Man, Wanrong
    Lin, Jie
    Dong, Yuan
    Liu, Liyuan
    Wang, Bo
    Wang, Huan
    Guo, Baolin
    Li, Congye
    Li, Fei
    Wang, Haichang
    Sun, Dongdong
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2020, 1866 (08):
  • [6] Puerarin alleviates skeletal muscle atrophy in type 1 diabetic rats
    YIN Lin
    CHEN Xi
    LI Na
    JIA Wei-hua
    WANG Nuo-qi
    HOU Bi-yu
    QIANG Gui-fen
    YANG Xiu-ying
    DU Guan-hua
    中国药理学与毒理学杂志, 2019, (10) : 927 - 927
  • [7] Canagliflozin bei diabetischer NierenerkrankungCanagliflozin in diabetic kidney disease
    Vojtech Pavlicek
    Die Diabetologie, 2023, 19 (8) : 936 - 937
  • [8] F2RL1 Inhibition Alleviates Lipotoxicity-Induced Kidney Injury Through the Hippo Pathway in Diabetic Kidney Disease
    Wang, Hui
    Wang, Wei
    Jiang, Yao
    Cui, Siyuan
    Kong, Yulin
    Chen, Yong Q.
    Zhu, Shenglong
    INFLAMMATION, 2024,
  • [9] Activation of Hippo pathway alleviates kidney injury in type 2 diabetic mice
    Wang, Y.
    Wang, L.
    Huang, Y.
    DIABETOLOGIA, 2024, 67 : S430 - S430
  • [10] Inhibition of GCN2 Alleviates Cardiomyopathy in Type 2 Diabetic Mice via Attenuating Lipotoxicity and Oxidative Stress
    Yuan, Juntao
    Li, Fang
    Cui, Bingqing
    Gao, Junling
    Yu, Zhuoran
    Lu, Zhongbing
    ANTIOXIDANTS, 2022, 11 (07)